Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00325689
Status:
COMPLETED
Last Update Posted:
2013-11-08
First Post:
2006-05-11
Brief Title:
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder
Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Organization Data
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Class:
INDUSTRY
Study ID:
CN138-397 ST
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Study Director
Old Organization:
Bristol-Myers Squibb
Collaborators
| Name | Class |
|---|---|
| Otsuka America Pharmaceutical | INDUSTRY |